REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.26+0.02 (+0.28%)
Close on Nov 18, 2026Market cap $479.26MP/E –Yield –
Regenxbio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Regenxbio's operating income for the twelve months ending Jun 30, 2026 was -$164.15M. For fiscal 2025 it was -$161.20M. The highest annual figure on record is $159.98M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$161.20M | – |
| FY2024 | Dec 31, 2024 | -$233.35M | – |
| FY2023 | Dec 31, 2023 | -$268.13M | – |
| FY2022 | Dec 31, 2022 | -$262.88M | -264.3% |
| FY2021 | Dec 31, 2021 | $159.98M | – |
| FY2020 | Dec 31, 2020 | -$119.23M | – |
| FY2019 | Dec 31, 2019 | -$149.00M | -269.1% |
| FY2018 | Dec 31, 2018 | $88.10M | – |
| FY2017 | Dec 31, 2017 | -$75.89M | – |
| FY2016 | Dec 31, 2016 | -$65.34M | – |
| FY2015 | Dec 31, 2015 | -$23.14M | – |
| FY2014 | Dec 31, 2014 | -$3.68M | – |
| FY2013 | Dec 31, 2013 | -$4.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$83.36M | -787.4% |
| Q4 FY2025 | Dec 31, 2025 | -$57.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$63.28M | – |
| Q1 FY2025 | Mar 31, 2025 | $12.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$62.08M | – |
| Q2 FY2024 | Jun 30, 2024 | -$56.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$63.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$63.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$64.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$73.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.77M | -118.4% |
| Q3 FY2022 | Sep 30, 2022 | -$71.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$62.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$71.53M | – |
| Q4 FY2021 | Dec 31, 2021 | $313.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$57.35M | -511.1% |
| Q2 FY2021 | Jun 30, 2021 | -$52.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.04M | – |
| Q4 FY2020 | Dec 31, 2020 | -$53.65M | – |
| Q3 FY2020 | Sep 30, 2020 | $13.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$41.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$37.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$40.32M | -1745.9% |
| Q3 FY2019 | Sep 30, 2019 | -$35.90M | – |
| Q2 FY2019 | Jun 30, 2019 | -$36.87M | -680.7% |
| Q1 FY2019 | Mar 31, 2019 | -$35.91M | -135.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.73M | – |
| Q2 FY2018 | Jun 30, 2018 | $6.35M | – |
| Q1 FY2018 | Mar 31, 2018 | $102.03M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.60M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.06M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.92M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.47M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.67M | – |
See a number that looks wrong?